This move is archived. Current quotes and coverage live on the stock page.
Follow MSCL
Satellos Bioscience Inc. is seeing a drop in its stock price, raising concerns about its market performance.
Today, Satellos Bioscience Inc. (MSCL.TO) is facing a tough day, with its stock down 2.51% to close at CA$13.60. This decline comes despite some recent positive news about its clinical programs and FDA designations.
Investor takeaway: Investors should be cautious, as the stock's decline might reflect broader market sentiments or specific concerns among shareholders.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$228.50M
52W high
$18.98
52W low
$7.56
1W change
-11.72%
Beta
1.15
Analyst Price Targets
Based on analyst covering MSCL · as of Sep 28, 2026
Wall Street analysts forecast MSCL stock price to rise 62.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.47
+62.2% Upside
Previously C$17.67 on Sep 17, 2026
Current Price
C$10.77
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
53.4%
Annualized
90-Day Vol
71.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$9.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.15 | C$8.44 – C$12.20 |
| 60 trading days | C$9.56 | C$7.37 – C$12.41 |
| 90 trading days | C$9.01 | C$6.55 – C$12.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Satellos Bioscience Inc. Market Cap: CA$290.6 Million
The company’s market cap is relatively modest, indicating investor caution amid ongoing developmental challenges.
Bull case
The recent FDA Fast Track Designation for SAT-3247 could speed up the drug's development timeline, which might lead to significant gains in the future.
Bear case
The current slide in stock price may show investor skepticism about the company's ability to meet expectations, especially given its lack of profit margins and ongoing development risks.
Advertisement
Market Reaction and Performance
Today, Satellos Bioscience Inc. is experiencing a decline in its stock price, down 2.51%. This drop could be influenced by broader market conditions or specific investor concerns. Even with the recent FDA Fast Track Designation for SAT-3247, aimed at expediting development for Duchenne Muscular Dystrophy, the market is reacting negatively.
Future Prospects and Challenges
While the Fast Track Designation could be a catalyst for future growth, Satellos faces significant challenges. The company has yet to report any profit margins, and investor confidence may be wavering as they await tangible results from its clinical programs. Potential investors should weigh the risks carefully before making decisions. For more details on their recent developments, check out the updates on their clinical programs and financial results.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
